Belgium· BE-AMP-SAM583831-00
Alymsys 25 mg/ml
A bevacizumab product containing bevacizumab, registered in Belgium by Mabxience Research. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Bevacizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FG01 (bevacizumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Bevacizumab · ATC L01FG01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of bevacizumab costs, country by country.
Normalised to the WHO defined daily dose (45 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Bevacizumab · price per daily dose (45 mg)
USD · FX 28 Sept 2026
- CH Switzerland$141.13
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Bevacizumab
- Manufacturer
- Mabxience Research
- Country
- Belgium (BE)
- ATC code
- L01FG01
- ATC class
- Bevacizumab
- Defined daily dose
- 45 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
22 interactions on record for bevacizumab.
Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Bevacizumab · interactions on record
22 records
- 6 severe
- 16 moderate
Most severe, free to view
- SunitinibL01EX01severe
- PanitumumabL01FE02severe
- PanitumumabL01XC08severe
- SunitinibL01XE04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Bevacizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaABEVMYBiosimilar Collaborations Ireland Limited, Dublin
- FinlandAbevmyBiosimilar Collaborations Ireland Limited
- PolandAbevmyBiosimilar Collaborations Ireland Ltd
- IrelandAbevmy 25 mg/mL concentrate for solution for infusionBiosimilar Collaborations Ireland Limited
- IcelandAbevmyBiosimilar Collaborations Ireland Limited
- SwedenAbevmy 25 mg/ml Koncentrat till infusionsvätska, lösningBiosimilar Collaborations Ireland Limited
- NorwayAlymsysMabxience Research SL
- United KingdomAbevmy 100mg/4ml concentrate for solution for infusion vialsBiocon Biologics Ireland Ltd
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Oyavas
- Iceland · Abevmy, Alymsys
- Liechtenstein · Abevmy, Alymsys
- Norway · Abevmy, Alymsys
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ab82a96d-6709-4114-8c44-5ef3c53af9fe GET /v1/drugs/ab82a96d-6709-4114-8c44-5ef3c53af9fe?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Alymsys 25 mg/ml",
"name_fr": "Alymsys 25 mg/ml",
"name_nl": "Alymsys 25 mg/ml",
"amp_code": "SAM583831-00",
"strengths": [
"25.0000"
],
"pack_count": 1,
"substances": [
"Bevacizumab",
"Disodium Phosphate",
"Sodium Phosphate Monobasic Monohydrate",
"Polysorbate 20"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Bevacizumab",
"authorisation_numbers": [
"EU/1/20/1509/002"
]
}See everything about bevacizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.